Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Firstline pembrolizumab plus chemo improves NSCLC outcomes

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.16
Views: 1685

Dr Corey Langer - University of Pennsylvania, Philadelphia, USA

Dr Corey Langer presents, at press conference at ESMO 2016, results from the KEYNOTE-021 trial.

The trial found that the addition of pembrolizumab, a PD-1 antibody, to standard first-line chemotherapy for treatment-naive advanced NSCLC achieved significantly longer progression free survival, a great objective response rate, and a well tolerated toxicity profile.

These results complement those presented by Dr Martin Reck, who presented results from KEYNOTE-024 which recommend pembrolizumab as a firstline therapy for NSCLC patients with high levels of PDL-1 expression.

More details are available in the trial data published in The Lancet.

Dr Langer spoke with ecancer about the findings here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation